



Supplimentary Tables

	Out Patients n (%)	Discharged n (%)	Deceased n (%)
Home	28 (25.2)	17 (12.9)	6 (4.5)
Office job	23 (20.7)	15 (11.4)	5 (3.8)
Technical support	14 (12.6)	21 (15.9)	10 (7.6)
Merchant	13 (11.7)	34 (25.8)	14 (10.6)
Public service	8 (7.2)	6 (4.5)	2 (1.5)
Nurse	6 (5.4)	2 (1.5)	1 (0.8)
General practitioner	5 (4.5)	3 (2.3)	1 (0.8)
Driver	5 (4.5)	11 (8.3)	5 (3.8)
Retired	4 (3.6)	10 (7.6)	4 (3.0)
Unemployed	3 (2.7)	9 (6.8)	2 (1.5)
Health technician	2 (1.8)	21 (15.9)	10 (7.6)
Unknown	---	4 (3.0)	3 (2.3)
Level of education			
High school or less	41 (36.9)	78 (59.1)	
More than highschool	70 (63)	54 (40.9)	

Supplementary Table I: Most frequent occupations and level of scholarship of patients who attended the institute for COVID-19 care.

Inflammatory parameters	Women	Men	p
BUN (mg/dl)	15.5 (12.7-27.25)	22 (16-31.5)	0.37
Creatinine (mg/dl)	0.8 (0.63-1.11)	1.02 (0.89-1.34)	0.003
Hemoglobin (g/dl)	14.1 (12.7-14.8)	15.7 (14.6-16.7)	<0.001
Lymphocytes (%)	12.9 (7.7-17.6)	8.7 (5-12.9)	0.019
Ferritin (ng/ml)	371 (108.2-792.8)	877 (514.8-1380)	<0.001
CPK (IU/ml)	72 (45.5-133)	135 (64-307)	0.009
D-dimer (ng/ml)	1569 (924.2-3340)	3658.5 (1219.7-8925)	0.01
Prothrombin (seconds)	10.9 (10.4-11.8)	11.4 (10.7-12.4)	0.041

Supplementary Table II: Differences between women and men in inflammatory parameters.

	Discharged n=66	Deceased n=53	p
Symptoms n (%)			
-Fever	50 (75.3)	43 (81.1)	0.512
-Cough	56 (84.8)	44 (83)	0.806
- Headache	34 (51.5.)	26 (50)	1
-Dyspnea	59 (89.4)	48 (90.6)	1
-Chest pain	17 (25.8)	3 (5.7)	0.006
-Anosmia	7 (10.6)	2 (3.8)	0.296
-Myalgias /arthralgias	34 (51.5)	24 (45.3)	0.581
-Asthenia / adynamia	21 (31.8)	17 (32.1)	1
-Diarrhea	8 (12.3)	10 (18.9)	0.441

Supplementary Table III: Differences in symptoms in hospitalized patients according to mortality.

	Discharged n=66	Deceased n=53	p
Basal drug therapy			
- Metformin	50 (75.8)	39 (75)	1
- Sulphonylurea	18 (27.3)	13 (25)	0.835
- Insulin	27 (40)	18 (34.6)	0.568
- DPP-4 inhibitor	9 (13.6)	4 (7.7)	0.383
- SGLT-2 inhibitor	2 (3.0)	0	-
- GLP1 agonist	-	-	
- Thiazolidinedione	2 (2)	1 (1.9)	1
- Angiotensin Converting Enzyme Inhibitors (ACEi)	9 (13.6) 14 (21.2)	7 (13.2) 12 (22.6)	1 1
- Angiotensin-II receptor antagonist (ARA)	7 (10.6)	3 (5.7)	0.509
- Calcium channel blockers	4 (6.1)	1 (1.9)	0.38055
- Beta blockers	6 (9.1)	5 (9.4)	1
- Diuretics	7 (10.6)	0	0.729
Insulin strategies			
- Regular	25 (37.9)	27 (50.9)	0.214
- NPH	32 (48.5)	12 (22.6)	0.006
- Infusion	1 (1.5)	9 (16.9)	0.007
- Basal-Bolus	4 (6)	4 (7.5)	0.991
- Mixed	3 (4.5)	1 (1.8)	0.325

Supplementary Table IV: Differences in treatment received according to mortality.

Hospitalization day	Discharged n / med (IQ 25-75)		Deceased n / med (IQ 25-75)		p
1	66	186 (144-272)	53	271 (181-335)	0.001
2	62	142.5 (104-216)	45	164 (118-231)	0.341
3	57	139 (111-174)	36	148.5 (121-185)	0.346
4	46	141.5 (113-194)	31	173 (147-213)	0.017
5	37	131 (102-176)	23	186 (161-230)	0.001
6	26	152 (108-196)	21	194 (144-228)	0.028
7	19	140 (107-180)	19	145 (124-228)	0.418
Week 2	3	169.6 (123-170)	8	207 (109-256)	0.776
Week 3	3	214.3 (122-214)	3	202.7 (122-203)	1
Week 4	1	170	2	159.2 (130-159)	1

Supplementary Table V: Average daily glycemic control between discharged and deceased patients.

	n (%)	Days (med,IQ)
Outpatient oxygen therapy	36 (73.4)	
L/min (median, interquartile range)	2 (1-3)	
Oxygen saturation(%) (median, interquartile range)	93 (91-95); 30 (15-48)	
Symptoms since discharge		
-Fever	2 (4.2)	2.5 (2.0-2.5)
-Cough	20 (41.7)	6 (5-15)
-Headache	20 (41.7)	5 (2-15)
-Dyspnea	16 (33.3)	4.5 (2-12.2)
-Chest pain	13 (27.1)	7 (3-15)
-Anosmia	13 (27.1)	3 (1.5-4.5)
- Myalgias / arthralgias	22 (45.8)	3.5 (2.7-22.7)
-Asthenia / adynamia	32 (66.7)	6 (2.5-42.5)
-Diarrhea	6 (12.5)	5 (2-14.2)
Body mass index (kg/m²)	27.9 (24.9-33.8)	
Weigh change (kg)	-5 (-10 a 0)	
Time for first evaluation by external physician (days)	10 (10-30)	
Number of subsequent consultations	2 (0-3)	
Drug therapy upon discharge (n=47)		
- Metformin	33 (70.2)	
-Sulphonylurea	6 (12.8)	
-Insulin	22 (18.5)	
-DPP-4 inhibitor	8 (6.7)	
-SGLT-2 inhibitor	3 (6.4)	
- GLP1 agonist	-	
-Thiazolidinedione	-	
-Without hypoglycemic agent	4 (8.5)	
Antihypertensive drugs (n=44)		
-Angiotensin converting enzyme inhibitors (ACEi)	3 (6.8)	
-Angiotensin-II receptor antagonist (ARA)	10 (22.7)	
-Calcium channel blockers	6 (13.6)	
-Beta blockers	2 (4.5)	
-Diuretic	2 (4.3)	

Supplementary Table VI: Evolution of patients with diabetes recovered from COVID-19.

